Cargando…
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsatisfactory. Many factors affect the outcome of a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923338/ https://www.ncbi.nlm.nih.gov/pubmed/33653420 http://dx.doi.org/10.1186/s40164-021-00211-8 |